The Latest Cardiac and Vascular News
ST. LOUIS, March 03, 2022 (GLOBE NEWSWIRE) — Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial results for the fourth quarter and full year ended December 31, 2021. “In 2021 we delivered significant revenue growth, drove a resurgence in adoption of […]
Anticipated departure of Jocelyn PINEAU, Chief Financial Officer and member of the Board of Directors, at June 30, 2022. Recruitment of a new senior Chief Financial Officer to support the development of Valbiotis as a major player in health nutrition. LA ROCHELLE, France–(BUSINESS WIRE)–Regulatory News: Valbiotis (FR0013254851 – ALVAL, PEA/SME […]
Watanabe brings deep experience in healthcare and medical devices STAMFORD – March 2, 2022 – H.I.G. Capital (“H.I.G.”), a leading global alternative investment firm with over $47 billion of equity capital under management, is pleased to announce that Gwen Watanabe has joined the firm’s dedicated life-science investment affiliate, H.I.G. BioHealth Partners, […]
VALHALLA, N.Y., March 2, 2022 /PRNewswire/ — Retia Medical today announced that it received a Declaration of Compatibility from Philips for its Argos Cardiac Output Monitor to interface with Philips IntelliBridge system on the IntelliVue patient monitoring systems. The Argos Monitor is now a compatible and “supported device” for Philips IntelliVue Patient […]
DENVER and WASHINGTON, March 2, 2022 /PRNewswire/ — DispatchHealth, the nation’s first comprehensive in-home high acuity medical provider, today announced its collaboration with The American College of Cardiology (ACC), a nonprofit professional medical society, to enhance the lives of cardiovascular disease patients. The first of its kind, the collaboration between DispatchHealth and ACC is designed to […]
Cohort 4 to Enroll Patients with Non-Obstructive Hypertrophic Cardiomyopathy SOUTH SAN FRANCISCO, Calif., March 02, 2022 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the opening of enrollment in Cohort 4 of REDWOOD-HCM (Randomized Evaluation of Dosing With CK-274 in Obstructive Outflow Disease in HCM), an ongoing Phase 2 clinical trial of aficamten, an investigational next-generation cardiac […]
SOUTH SAN FRANCISCO, Calif., March 01, 2022 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on February 28, 2022 it granted stock options to purchase an aggregate of 86,850 shares of common stock to eight new employees, whose employment commenced in February 2022, as a material inducement to […]
BRISBANE, Australia and EAGAN, Minn., March 02, 2022 (GLOBE NEWSWIRE) — Anteris Technologies Ltd (Anteris or the Company) Limited (ASX: AVR) announces the Company has entered a binding agreement to place 1,840,000 new Ordinary Shares (New Shares) raising USD 20 million ($A 28 million) to Perceptive Life Sciences Master Fund, […]
Business Associate Agreement and Clinical Trial Agreement with Additional Planned Studies and Commercial and Scientific Collaboration SANTA CLARA, Calif.–(BUSINESS WIRE)–HeartBeam, Inc. (NASDAQ: BEAT), a developmental stage digital healthcare company with a proprietary ECG telemedicine technology for heart attack detection, today announced it has signed a Business Associate Agreement (BAA) and Clinical […]
HANOVER, Germany–(BUSINESS WIRE)–Cardior Pharmaceuticals, a clinical-stage biotech company developing non-coding RNA (ncRNA)-based therapeutics for patients with cardiac diseases, today announced the expansion of its Scientific Advisory Board (SAB) with four newly appointed cardiology and RNA drug development experts. Johann Bauersachs, MD; Perry Elliott, MD; Gerasimos Filippatos, MD, PhD; and Barry […]
